Get started
Author

Jason M. Foulks

An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
2012 · Lauren Averett Byers, Lixia Diao, et al. · Clinical Cancer Research · 1,058
Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenecity of human platelets
2006 · Hansjörg Schwertz, Neal D. Tolley, et al. · The Journal of Experimental Medicine · 361
Epigenetic Drug Discovery: Targeting DNA Methyltransferases
2011 · Jason M. Foulks, K. Mark Parnell, et al. · SLAS DISCOVERY · 158
PDF
mTOR-dependent synthesis of Bcl-3 controls the retraction of fibrin clots by activated human platelets
2006 · Andrew S. Weyrich, Melvin M. Denis, et al. · Blood · 136
A Small-Molecule Inhibitor of PIM Kinases as a Potential Treatment for Urothelial Carcinomas
2014 · Jason M. Foulks, Kent J. Carpenter, et al. · Neoplasia · 95
Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth
2013 · K. Mark Parnell, Jason M. Foulks, et al. · Molecular Cancer Therapeutics · 71
Synthesis and Biological Evaluation of Pyrazolo[1,5-a]pyrimidine Compounds as Potent and Selective Pim-1 Inhibitors
2014 · Yong Xu, Benjamin G. Brenning, et al. · ACS Medicinal Chemistry Letters · 58
Discovery of 3-(trifluoromethyl)-1H-pyrazole-5-carboxamide activators of the M2 isoform of pyruvate kinase (PKM2)
2013 · Yong Xu, Xiao-Hui Liu, et al. · Bioorganic & Medicinal Chemistry Letters · 51
Intracellular PAF catabolism by PAF acetylhydrolase counteracts continual PAF synthesis
2007 · Jiawei Chen, Lili Yang, et al. · Journal of Lipid Research · 49
PDF
AXL Inhibitor TP-0903 Reduces Metastasis and Therapy Resistance in Pancreatic Cancer
2021 · Yuqing Zhang, Emily N. Arner, et al. · Molecular Cancer Therapeutics · 33
PDF
A yeast PAF acetylhydrolase ortholog suppresses oxidative death
2008 · Jason M. Foulks, Andrew S. Weyrich, et al. · Free Radical Biology and Medicine · 33
Genetic ablation of Pim1 or pharmacologic inhibition with TP-3654 ameliorates myelofibrosis in murine models
2021 · Avik Dutta, Dipmoy Nath, et al. · Leukemia · 31
TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth
2021 · Tsz-Yin Chan, Christina M. Egbert, et al. · Nature Communications · 31
PDF
Discovery of 4-phenyl-2-phenylaminopyridine based TNIK inhibitors
2012 · Koc-Kan Ho, K. Mark Parnell, et al. · Bioorganic & Medicinal Chemistry Letters · 31
Molecular glues: enhanced protein-protein interactions and cell proteome editing
2022 · Evita G. Weagel, Jason M. Foulks, et al. · Medicinal Chemistry Research · 29
PDF
PAF-acetylhydrolase expressed during megakaryocyte differentiation inactivates PAF-like lipids
2009 · Jason M. Foulks, Gopal K. Marathe, et al. · Blood · 24
Synthesis and structure–activity relationship of 2-arylamino-4-aryl-pyrimidines as potent PAK1 inhibitors
2013 · Yong Xu, Jason M. Foulks, et al. · Bioorganic & Medicinal Chemistry Letters · 18
AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2023 · R. Leo Sakemura, Mehrdad Hefazi, et al. · Cancer Immunology Research · 13
PDF
AXL promotes inflammatory breast cancer progression by regulating immunosuppressive macrophage polarization
2025 · Lan T. H. Phi, Yating Cheng, et al. · Breast Cancer Research · 9
PDF
Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy
2022 · Firas El Chaer, James McCloskey, et al. · Blood · 9
5-Azacytidine and decitabine induce C > G transversions in both murine and human cells
2025 · Ryan Bertoli, Dengchao Cao, et al. · Leukemia · 8
PDF
TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax
2023 · Anudishi Tyagi, Appalaraju Jaggupilli, et al. · Leukemia · 8
ASXL1 mutations are associated with a response to alvocidib and 5-azacytidine combination in myelodysplastic neoplasms
2023 · Vladimir Riabov, Qingyu Xu, et al. · Haematologica · 7
PDF
A Phase 1/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis
2024 · John O. Mascarenhas, Raajit Rampal, et al. · Blood · 6
Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients
2024 · Firas El Chaer, Lindsay A.M. Rein, et al. · Blood · 5
Works count: 150
Citation count: 2,373
H-index: 17
I10-index: 18
Year
Topic
Type